Other widely-used insulin brands at that price include Novo Nordisk’s Novolog and Sanofi’s Lantus. Amazon said its website will estimate the consumer’s insurance price.

Sanofi is cutting the list price of Lantus, its most widely prescribed insulin in the US, by 78% and establishing a $35 monthly cap for those with private insurance, the company announced Thursday.

Insulin prices charged by the three major drug manufacturers spiked over the past two decades. From 2002 through 2013, the average price of insulin nearly tripled, according to the American ...

Health policy experts say Eli Lilly's competitors—Sanofi, which makes Apidra and Lantus, and Novo Nordisk, which makes NovoLog and Levemir—are now facing increasing pressure to respond.

French pharmaceutical company Sanofi, one of the top three insulin manufacturers for the U.S., announced on Thursday it would be cutting the list price for its most prescribed insulin product Lantu… ...

Sanofi's Lantus insulin injection will see its price cut by 78%, the company announced Thursday. The out-of-pocket cost for all patients will be $35 for a monthly supply.

The GoodRx announcement comes more than six months after Sanofi pledged to slash the list price of Lantus, establishing a $35 cap on out-of-pocket costs for patients living with diabetes. HAYMARKET ..

Insulin manufacturers are making their products available to more people ... Sanofi established a $35 monthly cap on out-of-pocket costs for Lantus, its most widely prescribed insulin in the US, ...

In March of this year the three largest insulin manufacturers announced a dramatic reduction in the price of many commonly prescribed insulins and a monthly out-of-pocket (OOP) cap of $35 that went ...